National Development in the Use of Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease: Repeated Cross-Sectional Studies from 1998 to 2018
Recommendations for the treatment of chronic obstructive pulmonary disease (COPD) have shifted towards a more restrictive use of inhaled corticosteroids (ICS). We aimed to identify the nationwide development over time in the use of ICS treatment in COPD. We conducted a register-based repeated cross-...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-02-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/2/372 |
| _version_ | 1797298853106417664 |
|---|---|
| author | Allan Klitgaard Rikke Ibsen Jesper Lykkegaard Ole Hilberg Anders Løkke |
| author_facet | Allan Klitgaard Rikke Ibsen Jesper Lykkegaard Ole Hilberg Anders Løkke |
| author_sort | Allan Klitgaard |
| collection | DOAJ |
| description | Recommendations for the treatment of chronic obstructive pulmonary disease (COPD) have shifted towards a more restrictive use of inhaled corticosteroids (ICS). We aimed to identify the nationwide development over time in the use of ICS treatment in COPD. We conducted a register-based repeated cross-sectional study using Danish nationwide registers. On a yearly basis from 1998 to 2018, we included all patients in Denmark ≥ 40 years of age with an ICD-10 diagnosis of COPD (J44). Accumulated ICS use was calculated for each year based on redeemed prescriptions. Patients were divided into the following groups: No ICS, low-dose ICS, medium-dose ICS, or high-dose ICS. From 1998 to 2018, the yearly proportion of patients without ICS treatment increased (from 50.6% to 57.6%), the proportion of patients on low-dose ICS treatment increased (from 11.3% to 14.9%), and the proportion of patients on high-dose ICS treatment decreased (from 17.0% to 9.4%). We demonstrated a national reduction in the use of ICS treatment in COPD from 1998 to 2018, with an increase in the proportion of patients without ICS and on low-dose ICS treatment and a decrease in the proportion of patients on high-dose ICS treatment. |
| first_indexed | 2024-03-07T22:41:04Z |
| format | Article |
| id | doaj.art-d54e4e67a9f44f818bc72aacb1d6929a |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-07T22:41:04Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-d54e4e67a9f44f818bc72aacb1d6929a2024-02-23T15:08:38ZengMDPI AGBiomedicines2227-90592024-02-0112237210.3390/biomedicines12020372National Development in the Use of Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease: Repeated Cross-Sectional Studies from 1998 to 2018Allan Klitgaard0Rikke Ibsen1Jesper Lykkegaard2Ole Hilberg3Anders Løkke4Department of Regional Health Research, University of Southern Denmark, 5230 Odense, Denmarki2minds, 8000 Aarhus, DenmarkResearch Unit of General Practice, Department of Public Health, University of Southern Denmark, 6705 Esbjerg, DenmarkDepartment of Regional Health Research, University of Southern Denmark, 5230 Odense, DenmarkDepartment of Regional Health Research, University of Southern Denmark, 5230 Odense, DenmarkRecommendations for the treatment of chronic obstructive pulmonary disease (COPD) have shifted towards a more restrictive use of inhaled corticosteroids (ICS). We aimed to identify the nationwide development over time in the use of ICS treatment in COPD. We conducted a register-based repeated cross-sectional study using Danish nationwide registers. On a yearly basis from 1998 to 2018, we included all patients in Denmark ≥ 40 years of age with an ICD-10 diagnosis of COPD (J44). Accumulated ICS use was calculated for each year based on redeemed prescriptions. Patients were divided into the following groups: No ICS, low-dose ICS, medium-dose ICS, or high-dose ICS. From 1998 to 2018, the yearly proportion of patients without ICS treatment increased (from 50.6% to 57.6%), the proportion of patients on low-dose ICS treatment increased (from 11.3% to 14.9%), and the proportion of patients on high-dose ICS treatment decreased (from 17.0% to 9.4%). We demonstrated a national reduction in the use of ICS treatment in COPD from 1998 to 2018, with an increase in the proportion of patients without ICS and on low-dose ICS treatment and a decrease in the proportion of patients on high-dose ICS treatment.https://www.mdpi.com/2227-9059/12/2/372chronic obstructive pulmonary diseaseinhaled corticosteroidsinhaled medicationpharmacoepidemiologytreatment recommendationsnationwide development |
| spellingShingle | Allan Klitgaard Rikke Ibsen Jesper Lykkegaard Ole Hilberg Anders Løkke National Development in the Use of Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease: Repeated Cross-Sectional Studies from 1998 to 2018 Biomedicines chronic obstructive pulmonary disease inhaled corticosteroids inhaled medication pharmacoepidemiology treatment recommendations nationwide development |
| title | National Development in the Use of Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease: Repeated Cross-Sectional Studies from 1998 to 2018 |
| title_full | National Development in the Use of Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease: Repeated Cross-Sectional Studies from 1998 to 2018 |
| title_fullStr | National Development in the Use of Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease: Repeated Cross-Sectional Studies from 1998 to 2018 |
| title_full_unstemmed | National Development in the Use of Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease: Repeated Cross-Sectional Studies from 1998 to 2018 |
| title_short | National Development in the Use of Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease: Repeated Cross-Sectional Studies from 1998 to 2018 |
| title_sort | national development in the use of inhaled corticosteroid treatment in chronic obstructive pulmonary disease repeated cross sectional studies from 1998 to 2018 |
| topic | chronic obstructive pulmonary disease inhaled corticosteroids inhaled medication pharmacoepidemiology treatment recommendations nationwide development |
| url | https://www.mdpi.com/2227-9059/12/2/372 |
| work_keys_str_mv | AT allanklitgaard nationaldevelopmentintheuseofinhaledcorticosteroidtreatmentinchronicobstructivepulmonarydiseaserepeatedcrosssectionalstudiesfrom1998to2018 AT rikkeibsen nationaldevelopmentintheuseofinhaledcorticosteroidtreatmentinchronicobstructivepulmonarydiseaserepeatedcrosssectionalstudiesfrom1998to2018 AT jesperlykkegaard nationaldevelopmentintheuseofinhaledcorticosteroidtreatmentinchronicobstructivepulmonarydiseaserepeatedcrosssectionalstudiesfrom1998to2018 AT olehilberg nationaldevelopmentintheuseofinhaledcorticosteroidtreatmentinchronicobstructivepulmonarydiseaserepeatedcrosssectionalstudiesfrom1998to2018 AT andersløkke nationaldevelopmentintheuseofinhaledcorticosteroidtreatmentinchronicobstructivepulmonarydiseaserepeatedcrosssectionalstudiesfrom1998to2018 |